Dear Valued Visitor,

We have noticed that you are using an ad blocker software.

Although advertisements on the web pages may degrade your experience, our business certainly depends on them and we can only keep providing you high-quality research based articles as long as we can display ads on our pages.

To view this article, you can disable your ad blocker and refresh this page or simply login.

We only allow registered users to use ad blockers. You can sign up for free by clicking here or you can login if you are already a member.

Cheyne Capital Is Betting Big On M&A In 2016

Page 1 of 2

London-headquartered Cheyne Capital is one of the largest global alternative asset management firm based out of Europe. It was started by Jonathan Lourie and Stuart Fiertz – both of whom worked at Morgan Stanley together for 9 years- in 2000. Since the fund invests in a variety of securities across the globe, its exposure to US equities generally is only a fraction of its total assets under management (AUM) at any given point. However, it runs a fairly concentrated US equity portfolio and bets a large amount of money only on a handful of stocks. This trait of Cheyne Capital was again revealed by its recently submitted 13F filing with the Securities and Exchange Commission (SEC) for the reporting period ending December 31. According to the filing, the fund’s US equity portfolio at the end of December was worth $184.78 million and consisted of 32 long positions. However, the top five equity holdings of the fund alone accounted for 77.38% value of its equity portfolio at the end of 2015 and out of those five stocks,three were new entrants in the fund’s portfolio. In this article we are going to reveal and analyze those five stocks.

At Insider Monkey, we track hedge funds’ moves in order to identify actionable patterns and profit from them. Our research has shown that hedge funds’ large-cap stock picks historically underperformed the S&P 500 Total Return Index by an average of seven basis points per month between 1999 and 2012. On the other hand, the 15 most popular small-cap stocks among hedge funds outperformed the S&P 500 Index by an average of 95 basis points per month (read the details here).

Jonathan Lourie And Stuart Fiertz
Jonathan Lourie And Stuart Fiertz
Cheyne Capital

#5 EMC Corporation (NYSE:EMC)

– Shares Owned by Cheyne Capital (as of December 31): 958,731

– Value of Holding (as of September 30): $24.615 million

Since Cheyne Capital regularly employs an event-driven strategy, it isn’t a surprise that it initiated a stake in EMC Corporation (NYSE:EMC) during the fourth quarter of 2015. In October, hardware major Dell Inc. announced that it would buy EMC Corporation (NYSE:EMC) for $67 billion, making it the largest technology acquisition in history. Shares of EMC Corporation spiked in October right before the merger was officially disclosed following rumors of a potential deal, but since then they have given up those gains. Last month, EMC Corporation submitted a regulatory filing, which revealed that it would be laying off several of its employees this year in a major cost-cutting drive. For the last quarter, EMC posted earnings of $0.31 per share, missing the estimates of $0.36, while the full-year EPS of $0.65 was in line with expectations. During the fourth quarter, Seth Klarman’s Baupost Group initiated a stake in EMC Corporation and reported 29.25 million shares in its latest 13F filing.

#4 LivaNova PLC (NASDAQ:LIVN)

– Shares Owned by Cheyne Capital (as of December 31): 455,214

– Value of Holding (as of September 30): $27.03 million

London-based medical technology company LivaNova PLC (NASDAQ:LIVN) made a debut on the London Stock Exchange and NASDAQ in October last year. Shares of the company started drifting lower right after it started trading and are down by over 10% this year alone. According to the company’s last submitted quarterly report, it had a loss of $0.96 per share on revenue of $67.52 million for the quarter ending October 31, 2015. For the same quarter last year its generated EPS of $0.64 on revenue of $73.42 million. On December 29, LivaNova PLC (NASDAQ:LIVN) received a warning letter from the United States Food and Drug Administration (FDA) alleging certain violations of FDA regulations at its manufacturing facilities in Germany and Colorado. On January 5, the company provided its investors an update on this, stating that it believes that less than 1% of its 2016 consolidated sales could be impacted by this Warning Letter and the concerns raised by the FDA can be resolved without putting a toll on the company’s financials.

Follow Livanova Plc
Trade (LIVN) Now!

Page 1 of 2
Loading Comments...